0%

est. 2Y upside i

Healthcare

Software for pharmacies to move beyond dispensing

Rank

#2831

Sector

Healthcare IT

Est. Liquidity

~4Y

Data Quality

Data: Low

Equity upside is highly uncertain due to unavailable current valuation.

Last updated: July 3, 2026

Bull (20%)0%

Valuation unknown; cannot compute upside. Scenario assumes sustained growth and multiple expansion, but lacks entry valuation.

Base (35%)0%

Valuation unknown; cannot compute upside. Base case assumes moderate growth and multiple compression toward public comps.

Bear (45%)0%

Valuation unknown; cannot compute upside. Bear case assumes incumbents capture share and growth slows, with potential down round.

Est. time to liquidity~4.0 years

Preference Stack Risk

low

Funding Intensity

39%

Total funding of $3.69M is small relative to likely valuation (estimated $50-100M based on ARR), implying low preference overhang.

Dilution Risk

moderate

Recent venture debt suggests capital efficiency, but future equity raises may dilute; no major round imminent.

Secondary Liquidity

none

No secondary trading observed; illiquid shares.

Questions to Ask at the Interview

Strategic questions based on MedMe Health's data — designed to show you've done your homework.

  • 1

    “How does MedMe plan to compete against McKesson and Epic?”

  • 2

    “What is the unit economics per pharmacy and expansion path?”

  • 3

    “What is the current 409A valuation and option pool size?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.